NITD-688 shows antiviral activity against all four serotypes of dengue virus (DENV), with EC50 values of 8 to 38 nM[1].
NITD-688 shows antiviral activity against DENV-2 infected PBMCs, with an EC50 value of 0.94 nM[1].
NITD-688 directly binds to wild-type but not mutant NS4B protein[1].
NITD-688 (30 mg/kg, oral gavage, twice daily for 3 days) demonstrates excellent antiviral efficacy in infected AG129 mice[1].
NITD-688 (15-300 mg/kg, oral gavage, per day for 7 days) is well tolerated in rats and dogs (toxicology studies)[1].
References:
[1]. Moquin SA, et al. NITD-688, a pan-serotype inhibitor of the dengue virus NS4B protein, shows favorable pharmacokinetics and efficacy in preclinical animal models. Sci Transl Med. 2021 Feb 3;13(579):eabb2181.